Crohn's Disease, Nonalcoholic Fatty Liver Disease (NAFLD), Ulcerative Colitis, Vitamin D Deficiency
Conditions
Keywords
IBD, ulcerative colitis, Crohn's disease, NAFLD, biomarkers, vitamin D
Brief summary
The investigators intend to assess the role of several biomarkers in the prediction of relapse in IBD. Clinical, laboratory and endoscopic data will be gathered and a predictive score will be derived in order to assess the relapse risk at 1 year.
Detailed description
Patients with a confirmed diagnosis of IBD will be prospectively assessed on a yearly basis in order to assess relapse risk factors. Disease activity will be assessed using the Mayo score for UC patients and CDAI for Crohn's disease and endoscopic activity will be assessed using the Mayo endoscopic subscore for UC patients and the Simple Endoscopic Score for Crohn's Disease for CD patients. Serum and fecal biomarkers will be obtainted at each study visit (C-reactive protein, fecal calprotectin). Data about current and past medication for IBD will also be gathered.
Interventions
None listed
Sponsors
Clinical Hospital Colentina
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* ulcerative colitis or Crohn's disease * age over 18 * clinical remission * signed informed consent
Exclusion criteria
* pregnant women * refusal to sign informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical relapse | 1 year | clinical relapse as assessed by conventional scores for activity in IBD - Mayo or CDAI |
| Prevalence of NAFLD | 1 year | to assess the prevalence of nonalcoholic liver disease in IBD patients |
| prevalence of vitamin D deficiency | 1 year | to assess vitamin D deficiency and osteopenia among IBD patients |
Countries
Romania
Contacts
Primary ContactTheodor A Voiosu, MD
Outcome results
None listed